TRCT
CMPX icon

Tower Research Capital (TRC)’s Compass Therapeutics CMPX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123K Buy
23,252
+21,554
+1,269% +$124K ﹤0.01% 2025
2025
Q4 		$9.12K Sell
1,698
-4,341
-72% -$20K ﹤0.01% 3919
2025
Q3 		$21.1K Sell
6,039
-8,539
-59% -$27K ﹤0.01% 3262
2025
Q2 		$37.9K Sell
14,578
-7,944
-35% -$16.4K ﹤0.01% 3208
2025
Q1 		$42.8K Buy
22,522
+5,271
+31% +$14K ﹤0.01% 2332
2024
Q4 		$25K Buy
17,251
+12,917
+298% +$21.5K ﹤0.01% 3026
2024
Q3 		$7.97K Sell
4,334
-41,683
-91% -$52K ﹤0.01% 3992
2024
Q2 		$46K Buy
46,017
+45,220
+5,674% +$66K ﹤0.01% 3174
2024
Q1 		$1.58K Sell
797
-9,418
-92% -$16.3K ﹤0.01% 5240
2023
Q4 		$15.9K Buy
10,215
+4,077
+66% +$7.05K ﹤0.01% 3800
2023
Q3 		$12.1K Sell
6,138
-576
-9% -$1.42K ﹤0.01% 3925
2023
Q2 		$21.4K Sell
6,714
-1,141
-15% -$3.58K ﹤0.01% 3333
2023
Q1 		$26K Buy
7,855
+6,695
+577% +$26.3K ﹤0.01% 3145
2022
Q4 		$6K Buy
+1,160
New +$4.63K ﹤0.01% 4695
2022
Q1 		– Sell
-3,205
Closed -$10K – 6132
2021
Q4 		$10K Buy
+3,205
New +$10.6K ﹤0.01% 4538

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s CMPX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Compass Therapeutics (CMPX) stake by 1,269% in Q1 2026, buying an estimated $124K and bringing the position to 23,252 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #2025.

Tower Research Capital (TRC) first reported a position in CMPX in Q4 2021 and has held it in 15 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Tower Research Capital (TRC) held 23,252 shares of Compass Therapeutics worth $123K as of Q1 2026.
  • Tower Research Capital (TRC) bought 21,554 Compass Therapeutics shares in Q1 2026, an estimated $124K.
  • Compass Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2025 holding.
  • Tower Research Capital (TRC) first reported a position in Compass Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.